FENC has been the topic of several other reports. Wedbush upped their target price on Fennec Pharmaceuticals from $11.00 to $19.00 in a report on Monday, September 26th. Craig Hallum reiterated a buy rating and issued a $14.00 target price on shares of Fennec Pharmaceuticals in a report on Monday, August 8th. Capital One Financial began coverage on Fennec Pharmaceuticals in a report on Wednesday, September 7th. They issued an overweight rating and a $11.00 target price on the stock. Maxim Group increased their price target on Fennec Pharmaceuticals from $10.00 to $15.00 in a report on Thursday, September 29th. Finally, HC Wainwright upped their target price on Fennec Pharmaceuticals from $14.00 to $18.00 and gave the stock a buy rating in a research report on Thursday, October 20th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of Buy and a consensus price target of $15.40.
Fennec Pharmaceuticals Stock Performance
Shares of FENC stock opened at $8.71 on Monday. The business’s 50 day simple moving average is $7.95 and its 200 day simple moving average is $6.85. Fennec Pharmaceuticals has a one year low of $3.82 and a one year high of $8.88. The stock has a market capitalization of $228.53 million and a PE ratio of -10.62. The company has a debt-to-equity ratio of 8.81, a current ratio of 10.30 and a quick ratio of 10.30.
Institutional Inflows and Outflows
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
- Get a free copy of the StockNews.com research report on Fennec Pharmaceuticals (FENC)
- Three Ways To Win The Online Gambling Industry
- Santa Claus Rally? Here’s What Needs to Happen
- Will the Return of Bob Iger Return the Magic to Disney Stock?
- Is Ardelyx is A Buy After Slip in Early 2022
- Is Tesla A Bargain Now As It Trades At Two-Year Lows?
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.